Literature DB >> 30959263

Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.

Ramachandran Krishna Chandran1, Narayanan Geetha2, Kunnathur Murugesan Sakthivel3, Raveendran Suresh Kumar1, Kumarapillai Mohanan Nair Jagathnath Krishna4, Hariharan Sreedharan5.   

Abstract

The molecular mechanisms responsible for disease progression of CML are not conclusive. The main functional changes associated with disease evolution in CML was high proliferation rate, decreased apoptosis, blockade of differentiation, and strong resistance to chemotherapeutic agents. The current study analyzed the relative expressional profiles of genes related with proliferation, apoptosis, differentiation, and resistance to chemotherapeutic agents such as c-MYC, BAD, BCL-2, C/EBPα/-β and ABCB1 respectively in different clinical stages of CML by SYBR Green I quantitative real-time (qRT) PCR. We selected a total of 183 CML patients and 30 healthy control samples. The study populations were classified into four groups, including de novo CML-CP (50/183), CML-AP (32/183), CML-BC (51/183) and Imatinib Mesylate or IM resistant CML-CP (50/183) groups. qRT PCR analysis revealed that significant overexpression of c-MYC, ABCB1 and BCL-2 was observed in advanced phases and IM resistant CP of CML compared to healthy controls. Likewise, the mean expression level of BAD, C/EBPα/-β genes were found to be significantly down regulated. Present study concluded that the complex interplay of several candidate genes like overexpression of c-MYC, ABCB1, BCL-2 and down regulation of BAD, C/EBPα/-β played a significant role in the disease evolution and development of drug resistant in CML.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic Myeloid Leukemia; Disease progression; Imatinib Mesylate; Quantitative real time PCR

Year:  2019        PMID: 30959263     DOI: 10.1016/j.bcmd.2019.03.004

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  2 in total

1.  Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia.

Authors:  Pengliang Xin; Wenqian Xu; Xiongpeng Zhu; Chuntuan Li; Yan Zheng; Tingjin Zheng; Wenzhao Cheng; Qunyi Peng
Journal:  Cancer Manag Res       Date:  2019-08-22       Impact factor: 3.989

2.  Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells.

Authors:  Yuexian Zhang; Heng Chen; Yunfeng Shen; Xin Zhou
Journal:  J Immunol Res       Date:  2022-04-28       Impact factor: 4.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.